Some of Medtronic’s shareholders aren’t pleased about the structure of the $43 billion mega-merger with Covidien, which will stick some long-time backers with significant fees.
Not everyone is thrilled about the impending mega-merger of medtech titans Medtronic (NYSE:MDT) and Covidien (NYSE:COV). Although investors have rallied around the $43 billion deal and have lauded its structure as a corporate inversion, many stockholders are angry that they’re being stuck with a tax...
Read more